The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine ... and have large negative effects on patient quality of life, so new therapies ...

The decision came after a priority review of clinical data ... providers have had few options to offer patients much-needed symptom improvement." Spravato was previously used in combination ...

Just building on everything that J&J has established with Spravato, but making it much more convenient for the patient, much more convenient for the provider. JN: Maybe just a a little more ...

Spravato (esketamine) has become the first standalone therapy to be cleared by the US regulator for adult patients with treatment ... comes after a priority review and is based on the results ...

J&J's Spravato was FDA-approved in January as the ... The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no ...

The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s ... In addition, the design of a late-stage clinical program for patients with post-traumatic stress disorder is underway.